GDC-0449 concentrations and exposures of GDC-0449 after an intravenous (25 mg/dog) or oral (25 mg/capsule) dose, with or without administration of activated charcoal to male dogs
| Treatment | C24 h | C96 h | AUC0–168 |
|---|---|---|---|
| μM | μM | μM · h | |
| 25 mg p.o. | 0.650 ± 0.287 | 0.137 ± 0.093 | 48.4 ± 20.1 |
| 25 mg p.o. with + charcoal | 0.847 ± 0.733 | 0.004 ± 0.005 | 25.9 ± 21.2 |
| 25 mg i.v.a | 5.07 ± 0.61 | 3.16 ± 0.52 | 603 ± 57 |
| 25 mg i.v. with + charcoal | 4.49 ± 0.42 | 0.018 ± 0.016 | 173 ± 24 |
AUC0–168, area under the plasma concentration-time profile from time 0 to 168 h postdose; C24 h, plasma concentration at 24 h postdose; C96 h, plasma concentration at 96 h postdose.
↵a Data from intact male dogs from bile duct-cannulated dog study. Data presented here for comparative purposes.